| Drug ID: | Drug12 |
|---|---|
| Drug Name: | Caffeine |
| CID: | 2519 |
| DrugBank ID: | DB00201 |
| Modality: | Small Molecule |
| Groups: | approved |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT03358706, , NCT02760615 |
| Molecular Formula: | C8H10N4O2 |
| Molecular Weight: | 194.19 g/mol |
| Isomeric SMILES: | CN1C=NC2=C1C(=O)N(C(=O)N2C)C |
| Synonyms: | caffeine; 58-08-2; Guaranine; 1,3,7-Trimethylxanthine; Methyltheobromine; Theine; Thein; Cafeina; Koffein; Mateina |
| Phase 0: | 18 |
| Phase 1: | 110 |
| Phase 2: | 38 |
| Phase 3: | 45 |
| Phase 4: | 39 |
| Description: | A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine's most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes smooth muscle, stimulates cardiac muscle, stimulates diuresis, and appears to be useful in the treatment of some types of headache. Several cellular actions of caffeine have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide phosphodiesterases, antagonism of adenosine receptors, and modulation of intracellular calcium handling. [PubChem] |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt100 | 2519 | Caffeine | 5142 | PDE4B | Homo sapiens (human) | None | |
| dt101 | 2519 | Caffeine | 747 | DAGLA | Homo sapiens (human) | Activator | |
| dt102 | 2519 | Caffeine | 134 | ADORA1 | Homo sapiens (human) | Antagonist | |
| dt103 | 2519 | Caffeine | 4907 | NT5E | Homo sapiens (human) | 37713619 | Inhibitor |
| dt104 | 2519 | Caffeine | 135 | ADORA2A | Homo sapiens (human) | Antagonist | |
| dt105 | 2519 | Caffeine | 136 | ADORA2B | Homo sapiens (human) | 20164566 | Antagonist |
| dt106 | 2519 | Caffeine | 140 | ADORA3 | Homo sapiens (human) | 20164566 | Antagonist |
| dt107 | 2519 | Caffeine | 5144 | PDE4D | Homo sapiens (human) | Inhibitor | |
| dt108 | 2519 | Caffeine | 5140 | PDE3B | Homo sapiens (human) | Inhibitor | |
| dt109 | 2519 | Caffeine | 8654 | PDE5A | Homo sapiens (human) | Inhibitor |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT03358706 | A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis | PHASE1 | TERMINATED | Janssen Research & Development, LLC | Crohn Disease|Ulcerative Colitis | DRUG: Ustekinumab IV Infusion|DRUG: Ustekinumab S… | Details |
| NCT02760615 | Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study | PHASE4 | WITHDRAWN | Takeda | Colitis, Ulcerative|Crohn Disease | DRUG: Caffeine|DRUG: Losartan|DRUG: Omeprazole|DR… | Details |
| IRCT20150304021342N2 | The effects of dietary modification programme (low-fat, low-carb and high-protein diet) on mood status, fatigue and quality of life in patients with ulcerative colitis | Not Available | Not Recruiting | Esfahan University of Medical Sciences | Ulcerative colitis. Ulcerative colitis | Intervention 1: Intervention group: Patients who … | Details |
| NCT04624230 | Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | PHASE3 | RECRUITING | Pfizer | Ulcerative Colitis | DRUG: tofacitinib | Details |
| NCT06651281 | Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011) | PHASE3 | RECRUITING | Merck Sharp & Dohme LLC | Crohn Disease|Colitis, Ulcerative | DRUG: Tulisokibart|DRUG: Placebo to tulisokibart | Details |
| NCT04857112 | Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis | PHASE2 | ACTIVE_NOT_RECRUITING | Bausch Health Americas, Inc. | Ulcerative Colitis | DRUG: Low Dose MT-1303|DRUG: High Dose MT-1303|DR… | Details |
| NCT05986136 | Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease | PHASE2|PHASE3 | RECRUITING | Mostafa Bahaa | Inflammatory Bowel Diseases | DRUG: Mesalamine|DRUG: Dapagliflozin 10mg Tab | Details |
| NCT06353828 | Phase 2a Study to Evaluate IcBD-01 Enema in Active Ulcerative Colitis Patients | PHASE2 | ACTIVE_NOT_RECRUITING | CannaMore Biotechs | Ulcerative Colitis | DRUG: CBD, synthetic form|DRUG: Placebo | Details |
| NCT04478825 | Efficacy and Safety of Rectally Administered BBT-401-1S in Subjects With Ulcerative Colitis | PHASE1 | TERMINATED | Bridge Biotherapeutics, Inc. | Ulcerative Colitis | DRUG: BBT-401-1S | Details |
| NCT06570772 | Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio | PHASE3 | RECRUITING | Alvotech Swiss AG | Ulcerative Colitis | BIOLOGICAL: AVT16|BIOLOGICAL: Vedolizumab | Details |
| NCT01290042 | Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181. | PHASE1 | COMPLETED | Amgen | Ulcerative Colitis|Crohn's Disease | DRUG: AMG 181|OTHER: Placebo for AMG 181 | Details |
| NCT05507203 | ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 | PHASE3 | RECRUITING | Abivax S.A. | Ulcerative Colitis | DRUG: ABX464|DRUG: Placebo | Details |
| NCT00207688 | A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients | None | COMPLETED | Janssen Research & Development, LLC | Ulcerative Colitis | DRUG: Infliximab 5 mg/kg|DRUG: Infliximab 10 mg/k… | Details |
| NCT04677179 | A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) | PHASE2 | TERMINATED | Nektar Therapeutics | Colitis, Ulcerative | DRUG: LY3471851|DRUG: Placebo | Details |
| NCT02611830 | Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis | PHASE3 | COMPLETED | Takeda | Colitis, Ulcerative | DRUG: Vedolizumab 300 mg IV|DRUG: Placebo IV|DRUG… | Details |
| NCT02958865 | Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis | PHASE2 | COMPLETED | Pfizer | Ulcerative Colitis | DRUG: PF-06651600 or Placebo|DRUG: PF-06700841 or… | Details |
| NCT06420492 | Study of Novel Therapeutics for Acute Remedy of Colitis | PHASE2 | NOT_YET_RECRUITING | Brigham and Women's Hospital | Ulcerative Colitis|Ulcerative Colitis Chronic Mod… | DRUG: BRS201 | Details |
| NCT03943550 | Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC) | PHASE1 | TERMINATED | Hoffmann-La Roche | Ulcerative Colitis | DRUG: RO7049665|DRUG: Placebo | Details |
| NCT04133194 | Adherence of a 1.600 mg Single Tablet 5-ASA Treatment of Ulcerative Colitis | PHASE4 | RECRUITING | Flemming Bendtsen | Ulcerative Colitis | DRUG: Mesalazine|DRUG: Mesalazine | Details |
| NCT02392221 | Impact of Therapeutic Strategies in the Pediatric Inflammatory Bowel Disease: a Population Based Study (1988-2011). | None | COMPLETED | Centre Hospitalier Universitaire, Amiens | Pediatric Inflammatory Bowel Disease | None | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S04 | T-cell homing and retention | T-cell trafficking | vedolizumab; anti-MAdCAM1 antibodies ; etrolizumab | Inhibition of the interaction between α4β7 integrins on T c… | Details |
| S06 | Anti-fibrosis | fibrosis; tissue remodelling | GS-5745; STNM01 | Tissue remodelling and destruction in patients with IBD is … | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
Does caffeine have a double-edged sword role in inflammation and carcinogenesis…
PMID: 37072923
Year: 2023
Relationship Type:
Association
Score: 7.5
Caffeine (1,3,7-trimethylxanthine, also abbreviated to CAF) is a natural chemical with stimulant effects and is commonly included in many drinks and …
Association Between Caffeine Intake and Bowel Habits and Inflammatory Bowel Dis…
PMID: 40600201
Year: 2025
Relationship Type:
Association
Score: 6.5
BACKGROUND: The effect of caffeine in coffee, a popular beverage, on gastrointestinal symptoms has been the subject of ongoing debate worldwide. The …
Unraveling the link between plasma caffeine concentrations and inflammatory bow…
PMID: 38211690
Year: 2024
Relationship Type:
Association
Score: 6.5
BACKGROUND: Caffeine is believed to possess anti-inflammatory properties, yet direct population-based evidence regarding its impact on inflammatory b…
Coffee and caffeine intake reduces risk of ulcerative colitis: a case-control s…
PMID: 38073066
Year: 2024
Relationship Type:
Association
Score: 6.5
BACKGROUND AND AIM: Although diet is one of the potential environmental factors affecting ulcerative colitis (UC), evidence is not sufficient to draw…